Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jin Hyun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Byun, Ja Min | - |
dc.contributor.author | Kim, Ki Hwan | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Choi, In Sil | - |
dc.contributor.author | Kim, Hee-Jun | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Kim, Tae-Yong | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Oh, Do Youn | - |
dc.contributor.author | Kim, Tae-You | - |
dc.date.available | 2019-03-08T07:36:58Z | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 1738-6756 | - |
dc.identifier.issn | 2092-9900 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/3599 | - |
dc.description.abstract | Purpose: This study aimed to evaluate the efficacy and safety of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy beyond standard treatment for anthracycline-and taxane-pretreated metastatic breast cancer (MBC). Methods: We consecutively enrolled 158 MBC patients who underwent CMF chemotherapy in a palliative setting at two academic hospitals in Korea between 2002 and 2016. Results: The median age of the 158 enrolled patients was 51 years (range, 30-77 years). The enrolled patients were treated with a median of 5 lines of systemic treatment (range, 2-11) before CMF therapy, and the median time from diagnosis of MBC to CMF administration was 36.0 months (range, 7.1-146.7 months). The median number of cycles of CMF treatment was 3 (range, 1-19), and the relative dose intensity was 90.4%. The toxicity profile was mild, with an observed 3.1% of grade 2 and 5.0% of grade 3/4 neutropenia. Among 147 patients (93.0%) whose response to CMF was evaluated, the response rate was 10.9% (16/147), with complete response (CR) in one and partial response (PR) in 15. In addition, the disease control rate (calculated as CR+PR+stable disease) was 44.2% (65/147). The median progression-free survival and overall survival were 3.1 months (95% confidence interval [CI], 2.7-3.6) and 9.4 months (95% CI, 7.1-11.6), respectively. Conclusion: CMF therapy is effective and tolerable as salvage treatment for heavily pretreated MBC. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN BREAST CANCER SOC | - |
dc.title | Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis | - |
dc.type | Article | - |
dc.identifier.doi | 10.4048/jbc.2017.20.4.347 | - |
dc.identifier.bibliographicCitation | JOURNAL OF BREAST CANCER, v.20, no.4, pp 347 - 355 | - |
dc.identifier.kciid | ART002300502 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000419564500005 | - |
dc.identifier.scopusid | 2-s2.0-85039740011 | - |
dc.citation.endPage | 355 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 347 | - |
dc.citation.title | JOURNAL OF BREAST CANCER | - |
dc.citation.volume | 20 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Breast neoplasms | - |
dc.subject.keywordAuthor | Cyclophosphamide | - |
dc.subject.keywordAuthor | Fluorouracil | - |
dc.subject.keywordAuthor | Methotrexate | - |
dc.subject.keywordAuthor | Palliative care | - |
dc.subject.keywordPlus | SURGICAL ADJUVANT BREAST | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | CARCINOMA PATIENTS | - |
dc.subject.keywordPlus | B ANALOG | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | TAXANE | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.